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ABSTRACT
Introduction Injecting- related bacterial and fungal 
infections are a common complication among people 
who inject drugs (PWID), associated with significant 
morbidity and mortality. Invasive infections, including 
infective endocarditis, appear to be increasing in incidence. 
To date, preventive efforts have focused on modifying 
individual- level risk behaviours (eg, hand- washing and 
skin- cleaning) without much success in reducing the 
population- level impact of these infections. Learning from 
successes in HIV prevention, there may be great value in 
looking beyond individual- level risk behaviours to the social 
determinants of health. Specifically, the risk environment 
conceptual framework identifies how social, physical, 
economic and political environmental factors facilitate and 
constrain individual behaviour, and therefore influence 
health outcomes. Understanding the social and structural 
determinants of injecting- related bacterial and fungal 
infections could help to identify new targets for prevention 
efforts in the face of increasing incidence of severe disease.
Methods and analysis This is a protocol for a systematic 
review. We will review studies of PWID and investigate 
associations between risk factors (both individual- 
level and social/structural- level) and the incidence of 
hospitalisation or death due to injecting- related bacterial 
infections (skin and soft- tissue infections, bacteraemia, 
infective endocarditis, osteomyelitis, septic arthritis, 
epidural abscess and others). We will include quantitative, 
qualitative and mixed methods studies. Using directed 
content analysis, we will code risk factors for these 
infection- related outcomes according to their contributions 
to the risk environment in type (social, physical, 
economic or political) and level (microenvironmental or 
macroenvironmental). We will also code and present risk 
factors at each stage in the process of drug acquisition, 
preparation, injection, superficial infection care, severe 
infection care or hospitalisation, and outcomes after 
infection or hospital discharge.
Ethics and dissemination As an analysis of the 
published literature, no ethics approval is required. 
The findings will inform a research agenda to develop 
and implement social/structural interventions aimed at 
reducing the burden of disease.
PROSPERO registration number CRD42021231411.
INTRODUCTION
Injecting- related bacterial infections are very 
common among people who inject drugs 
(PWID), with up to 39% of PWID reporting 
skin infections within the past month and 70% 
reported lifetime prevalence.1 If not effec-
tively treated, superficial infections can prog-
ress and spread through the bloodstream, 
leading to life- threatening infections such as 
infective endocarditis, osteomyelitis, septic 
arthritis or epidural abscess.2 Pathogenic 
bacteria or fungi may be introduced directly 
Strengths and limitations of this study
 ► Injecting- related bacterial and fungal infections are 
a common problem among people who inject drugs 
(PWID), associated with significant morbidity and 
mortality.
 ► Understanding the social and structural deter-
minants of injecting- related bacterial and fungal 
infections could help to identify new targets for pre-
vention efforts, in the face of increasing incidence of 
severe disease.
 ► People with lived and living expertise of injection 
drug use, as well as practicing clinicians caring for 
PWID with injecting- related infections, and experi-
enced qualitative, quantitative and mixed methods 
researchers, were involved in the development of 
the protocol and will participate in analysis and 
synthesis.
 ► Reviewing quantitative, qualitative and mixed meth-
ods studies enables a broad scope and the inclusion 
of important contextual information that may not be 
captured in quantitative studies alone.
 ► This review only includes studies with infection- 
related outcomes, and so may not include some 
studies with risk factors for infection (eg, hand- 
washing and skin- cleaning) as outcomes.
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into the bloodstream as endogenous skin flora, or from 
non- sterile injecting equipment or contaminated drugs.3 
As a result, PWID face extremely high risk of disability 
or death from severe bacterial and fungal infections that 
require hospitalisation for antibiotics and/or surgery.4–9 
The incidence of severe bacterial and fungal infections 
is increasing among PWID in Canada,10–12 the United 
Kingdom,13 the USA,14–19 Australia20 and Sweden.21 A 
recent modelling study suggests that one in five PWID 
in the USA may die of infective endocarditis alone over 
the next 10 years.19 Better approaches to prevention are 
urgently needed.
To date, prevention efforts for injecting- related bacte-
rial and fungal infections have primarily focused on 
changing individual- level risk behaviours,1 22 including 
hand- washing before drug preparation,23 skin- cleaning 
before injecting24 and avoiding subcutaneous or intramus-
cular injections.25 Although individual- level interventions 
may be effective for people who due to their socioeco-
nomic situation can adopt these practices,26 27 they have 
not translated into reductions in the population- level 
incidence of severe bacterial and fungal infections, which 
continue to rise.
An appreciation for the importance of social and 
structural determinants of health has emerged from 
the understanding that individual health behaviours are 
shaped by contextual factors.28–32 The ‘risk environment’ 
conceptual framework, as developed by Rhodes et al,33–36 
describes how interactions between social and structural 
factors external to the individual influence individual 
behaviours, and therefore structure or create health 
harms.37 The risk environment framework has informed 
clinical and public health efforts at reducing other drug- 
related harms, including HIV transmission,33 36 38 hepa-
titis C virus (HCV) treatment39 and drug overdoses.29 40 
Better understanding of the social determinants of health 
can help to shift beliefs about responsibility and risk from 
individual behaviours to the places and social situations 
in which individuals exist, and inform the development 
of innovative interventions addressing both social and 
individual- level factors.36 41
Like other drug- related harms, risk for injecting- 
related bacterial and fungal infections also likely reflects 
contributions of multiple, interacting factors external 
to individuals that influence risk behaviours and there-
fore shape health outcomes. For example, homelessness 
may constrain an individual’s ability to wash their hands 
or use sterile water for injecting,42 and policy constraints 
on needle and syringe programs (from criminalisation to 
reduced operating hours) create a situation in which an 
individual is more likely to reuse a blunted or contami-
nated needle. Stigma and criminalisation of people who 
use drugs may keep people away from primary health-
care, causing superficial bacterial infections to remain 
untreated and progress to enter the bloodstream. In 
response to the alarming increases in incidence, calls 
to enhance understanding of the social determinants 
of injecting- related bacterial and fungal infections have 
emerged from both PWID43 and academic communi-
ties.2 4 26 44 Learning from the successes of HIV- prevention 
efforts in particular, mapping the risk environment for 
injecting- related bacterial and fungal infections could 
inform new prevention efforts that target social and struc-
tural causes.45 46
Objectives
To better understand the risk for injecting- related bacte-
rial and fungal infections among PWID, we seek to 
conduct a systematic mixed studies review (of quantita-
tive, qualitative and mixed methods evidence) to identify 
social and structural determinants of these infections 
among PWID, informed by the risk environment frame-
work. The proposed review will seek to answer the ques-
tion, ‘Among people who inject drugs (PWID), what 
social and structural factors are associated with the devel-
opment, treatment, and outcomes of injecting- related 
bacterial and fungal infections?’
METHODS AND ANALYSIS
This systematic review protocol follows the Preferred 
Reporting Items for Systematic Review and Meta- Analysis 
Protocols guideline47 48 and is informed by guidance on 
conducting systematic reviews of association (aetiology) 
by the Joanna Briggs Institute49 and on conducting 
and reporting mixed studies reviews by Pluye and 
colleagues50 51 and by Tricco and colleagues.52 We plan 
to conduct this study over 12 months following the initial 
full database search on 18 February 2021.
‘Mixed studies reviews’ incorporate synthesis of quan-
titative, qualitative and mixed methods studies; they are 
one of the several emerging methods for systematically 
incorporating evidence from diverse methodologies (eg, 
integrative review, realist review, meta- narrative review 
and critical interpretive synthesis).50 52 53 Mixed studies 
reviews use a mixed methods approach.54 55 They are 
particularly useful for research questions like ours that 
require detailed contextual information available from 
qualitative and mixed methods studies, and for synthesis 
plans like ours that incorporate a qualitative content anal-
ysis directed by existing theories and conceptual frame-
works.50 52
We have searched the PROSPERO registry of system-
atic reviews and found none in progress related to our 
objectives.
Conceptual framework
The risk environment framework is the most prominent 
social–ecological model for substance use research; it 
comprises risk factors external to individuals, considering 
types and levels of environmental influence.34 35 37 56 As 
first developed in the context of HIV prevention, the 
risk environment framework describes four different 
types of environmental influences: social, physical, 
economic and policy. These can occur at two different 
levels, microenvironmental or macroenvironmental.38 
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Microenvironmental factors operate at the level of inter-
personal relationships, community and group norms, 
and institutional or organisational responses.36 This 
could include local norms about the culture of substance 
use and acceptability of receptive sharing or reuse of 
potentially contaminated injecting equipment among 
PWID (a social factor), or increasing housing prices (an 
economic factor) contributing to homelessness and lack 
of access to soap and water (physical factors). Macroenvi-
ronmental factors operate at the level of states, societies, 
and laws, and interact with microenvironmental factors.36 
This could include state policing crackdowns on heroin 
importation leading instead to increased importation of 
fentanyl (a policy factor), which has a shorter half- life and 
associated risks of increased injecting frequency.57
Eligibility criteria
Informed by the Population, Exposures, Outcomes 
approach,49 we will include peer- reviewed papers 
describing eligible studies according to the following 
criteria.
Study designs
We will include studies measuring quantitative associ-
ations between exposures and outcomes of interest (as 
described below), and studies reporting qualitative data 
on relationships between experiences of exposures and 
outcomes. We will exclude case- reports and case series 
that do not include analyses of association, and we will 
exclude reviews, commentaries and editorials, as they do 
not include the original data.
Participants
We will include studies examining PWID of any age or 
nationality. By PWID, we are referring to people who 
inject opioids (eg, heroin, fentanyl, hydromorphone and 
morphine), stimulants (eg, cocaine and methamphet-
amines) or other psychoactive substances via intrave-
nous, intramuscular, or subcutaneous routes. We expect 
there to be differences between studies in how PWID 
are operationally defined (eg, ever injected or recently 
injected in past year or past 3 months).1 Taking a broad 
perspective, we will include studies that identify partici-
pants as PWID at risk for injecting- related infections, 
and not limit this to self- reported current or recent 
injecting. Many PWID transition back and forth between 
injection and non- injection routes of consumption,58 59 
and PWID who have stopped injecting may experience 
persistently increased risk for invasive infections such 
as endocarditis, due to prior damage to vasculature and 
heart valves.2 Studies that focus only on people who inject 
performance- enhancing drugs (eg, anabolic steroids) or 
gender- affirming hormones will be excluded as these are 
not psychoactive substances.
Exposures
We will include studies addressing risk factors or determi-
nants for injecting- related bacterial and fungal infections 
among PWID, taking a broad perspective. In addition to 
studies that directly survey individual participants about 
potential risk factors, we will consider studies investi-
gating potential associations with social or structural risk 
factors at microenvironmental and macroenvironmental 
levels. We will also include studies of interventions that 
aim to reduce risk, including educational, behavioural 
or structural (eg, community mobilisation or policy 
change) interventions.26 27 46 Studies that only report on 
individual- level risk factors (eg, skin- cleaning) will be 
included in the search, and then classified separately in 
the data synthesis.
Outcomes
Outcomes of interest include incidence of, hospitalisa-
tion with, or mortality due to, injecting- related bacterial 
and fungal infections. Bacterial and fungal infections 
include skin and soft- tissue infections (cellulitis, abscess, 
necrotising fasciitis), bloodstream infections (bacter-
aemia), vascular infections (endocarditis, septic or suppu-
rative phlebitis), bone and joint infections (osteomyelitis, 
septic arthritis or discitis) and central nervous system 
infections (epidural abscess, brain abscess, meningitis or 
encephalitis). We will also include as outcomes, diseases 
caused by pathogenic bacteria and fungi associated 
with drug supply, preparation and injecting practices, 
including tetanus,22 botulism,3 invasive group A strep-
tococcal disease,60 as well as methicillin- sensitive Staph-
ylococcus aureus and methicillin- resistant Staphylococcus 
aureus (MRSA).61 We will exclude studies identifying only 
non- injecting- related bacterial and fungal infections as 
outcomes, such as tuberculosis, pneumonia, chlamydia 
or gonorrhoea, and bacterial infections that are primarily 
sexually transmitted, for example, syphilis.
We will extract all outcomes as reported. We expect 
there to be many different methods for identifying these 
outcomes, including participant self- report of infection 
or hospitalisation, administrative records of hospital 
admission and mortality records from vital statistics.
Time frame, setting and language
We will include studies published between 1 January 
2000, and the planned search date, 18 February 2021, 
to capture contemporary research that would be more 
likely to inform policy and clinical practice. There will be 
no restrictions by study setting. We will include articles 
in English and French. A list of potentially relevant titles 
reported in other languages will be provided as an online 
supplemental appendix.
Information sources
We will search PubMed, EMBASE, Scopus, CINAHL and 
PsycINFO databases. Electronic database searches will 
be supplemented by manually reviewing reference lists 
of included studies, and forward ‘snowball’ searching by 
identifying articles that cite included studies.62 We will 
also circulate a bibliography of the included articles to the 
systematic review team, which includes people with lived 
(past) and living (current) expertise of injection drug 
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use and clinicians who care for people with injection- 
associated infections. We will include articles identified 
from the personal files of the systematic review team that 
were not identified in the bibliography.
Search strategy
Our search strategy is informed by several key existing 
systematic reviews or review protocols. A 2017 system-
atic review identified prevalence and individual- level risk 
factors for injecting- related injuries and diseases among 
PWID, including bacterial infections.1 Previous systematic 
reviews have applied the risk environment framework to 
understand HIV transmission,33 HIV63 and HCV39 treat-
ment access, HIV disease progression,64 providing or 
receiving assistance with the transition to injection drug 
use,65 and ‘safer environment interventions’41 among 
PWID. Two published protocols of systematic reviews in 
progress focused on health services and interventions 
to treat or prevent viral and bacterial infections among 
PWID.66 67
The final search strategy will be developed by our 
review team in consultation with health information 
specialist- librarians with systematic review experience. 
We conducted a pilot search in PubMed and validated 
by checking for inclusion of key, recent studies known 
to the authors that assessed either risk factors for severe 
bacterial or fungal infections among PWID,68 69 social/
structural determinants of bacterial infections among 
PWID42 70–73 or complex interventions to reduce risk of 
bacterial infections among PWID26 (online supplemental 
appendix table 1). This validation process led to several 
iterative changes, including specific search terms related 
to ‘acidifiers’ and ‘groin injecting’. See table 1 for the 
draft search strategy in PubMed, which identified 1752 
potentially relevant sources on 1 February 2021.
Data management and reference selection
Search results will be uploaded into Covidence, a cloud- 
based software programme, where they can be automati-
cally checked for de- duplication. Two reviewers will screen 
titles and abstracts against the inclusion criteria. We will 
obtain full text reports for all titles that appear to meet the 
inclusion criteria, or for where there is uncertainty. Two 
reviewers will screen these full text reports and mark each 
as included or excluded, recording reasons for exclusion. 
We will resolve discrepancies through discussion.
Data collection process
The team will develop and pilot- test a data extraction 
form, which can be applied in Covidence. We will extract 
information on the following:
 ► Study date (or publication date, if study date 
unavailable).
 ► Study country/region.
 ► Methodology (quantitative, qualitative or mixed 
methods).
 ► Study design.
 ► Sample size and demographic characteristics (age, 
gender, race/ethnicity).
 ► Inclusion criteria and definition of PWID.
 ► Sampling methods and recruitment setting (eg, 
community recruitment, needle exchange clients, 
clinic, hospital).
 ► Outcomes reported (incident infection/diagnosis, 
clinic visit, emergency department visit, hospital 
admission or death).
 ► Outcome operational criteria (self- reported, medical 
record review and administrative data).
 ► Infections reported (skin and soft- tissue infections at 
injection sites (e.g. abscess, cellulitis), bacteraemia, 
infective endocarditis, osteomyelitis, septic arthritis or 
other).1
 ► Exposures, risk factors or interventions assessed 
(including operational criteria).
 ► Measures of association between risk factors and 
outcomes (for quantitative and mixed methods 
studies).
 ► Summary of findings.
 ► Implications for policy and/or practice, as reported 
by authors.66
 ► Implications for research, as reported.
 ► Gaps identified, as reported.
Critical appraisal/risk of bias assessment
We will apply a formal, validated critical appraisal tool for 
mixed studies reviews, the Mixed Methods Appraisal Tool, 
2018 edition, which is designed for use with quantitative, 
qualitative and mixed methods studies.74 74 75 It includes 
the following five core quality criteria for five categories of 
study designs: (a) qualitative, (b) randomised controlled/
interventional, (c) non- randomised controlled, (d) quan-
titative descriptive and (e) mixed methods. This tool does 
not assign an overall quality score; rather, we will consider 
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each item in the risk of bias assessment independently. 
Owing to the broad scope of this review, we will not 
exclude studies deemed low quality. Study quality and risk 
of bias will inform interpretation of the data.
Data synthesis and analysis
We will perform data synthesis and analysis over several 
stages. We will perform a quantitative tabular synthesis of 
included studies, by year; country/region; methodology 
(quantitative, qualitative or mixed methods), infection 
type (cellulitis, endocarditis, etc.) and outcome (incident 
infection, care of superficial infection, care of severe 
infection/hospitalisation or outcomes after infection).
We will then conduct a qualitative, directed content 
analysis, as described by Hsieh and Shannon,76 to map 
the risk environment for injecting- related bacterial and 
fungal infections. We will first code each included expo-
sure or risk factor according to the risk environment 
framework as individual- level or social/structural. Social/
structural factors are those that are external to the indi-
vidual, and together make up the risk environment. We 
will then code each social/structural factor according to 
the type (social, economic, political or physical) and level 
(macroenvironmental or microenvironmental) of the risk 
environment. We will use a hybrid deductive–inductive 
approach, as described by Pluye and Hong50; we will start 
with the existing risk environment conceptual framework 
but allow for new concepts related to the classification of 
specific factors to emerge. To improve reliability, coding 
will be performed in tandem by a reviewer pair for three 
studies, with discrepancies resolved through discussion. 
Coding will then be discussed with the whole review team 
to identify improvements to the coding approach and 
framework. The remaining studies will be coded by one 
reviewer. We will present a tabular synthesis categorising 
each social/structural factor according to type and level 
in the risk environment framework,49 and a narrative 
synthesis of the existing evidence for each social/struc-
tural factor.39 See table 1 for the model table framework.
To explore how different macroenvironmental and 
microenvironmental factors influence individual- level 
risk behaviours, we will present a narrative synthesis of 
identified individual- level and social/structural factors 
affecting each step of a potential pathway from (a) drug 
acquisition; (b) drug preparation; (c) drug injection; (d) 
development of and care for superficial infections (eg, 
self- treatment or primary/emergency department care); 
(e) development of and care for severe or invasive infec-
tions (eg, self- care or hospital care) and (f) outcomes 
after infection or hospital discharge, including infection- 
related mortality.2 See figures 1 and 2 for illustrative 
schematics of how macroenvironmental and microenvi-
ronmental factors influence individual- level factors and 
may increase risks of injecting- related bacterial infections 
at two different stages in the pathway from drug acqui-
sition to outcomes after severe/invasive infections. We 
plan to develop and refine these figures to reflect find-
ings of the review. Note that because this review includes 
only studies with infection- related outcomes, we may 
not identify or include all published studies that identify 
determinants of intermediate risk factors or behaviours; 
Figure 1 Illustrative schematic of a potential risk environment for injecting- related bacterial and fungal infections, as it may 
structure or create infection risk during the process of drug injection/consumption. Environmental factors, which are external 
to individuals, interact to influence individual- level factors and health behaviours across stages of a potential pathway: drug 
acquisition; drug preparation; drug injection; treatment of superficial injection- site bacterial and fungal infections (eg, in primary 
care or emergency departments); treatment of severe/invasive bacterial and fungal infections (eg, in hospital for intravenous 
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for example, some studies identifying determinants 
of skin cleaning before injecting may not be included 
in this review if they do not consider infection- related 
outcomes.
If we identify sufficient quantitative data, we will 
conduct a meta- analysis of summary effects of association 
between social/structural factors (eg, homelessness) and 
injecting- related infection outcomes among PWID (eg, 
hospitalisation with any severe injecting- related bacterial 
or fungal infection) identified in our content analysis. 
Where available, we will extract measures of association 
adjusted for confounding, including point estimates and 
standard errors. To assess feasibility, we will evaluate clin-
ical and methodological heterogeneity by comparing 
study design, sample characteristics and operational defi-
nitions of exposures and outcome.65 77 We will measure 
statistical variability between studies using I2 statis-
tics.65 77 78
Patient and public involvement
The research team includes people with lived/living 
expertise of injection drug use and clinicians caring 
for PWID with bacterial and fungal infections. The 
research questions and analysis approach have been 
designed collaboratively, and build on existing relation-
ships between authors with lived/living expertise and 
academic/medical expertise.79–81 The topic was inspired 
by the deaths of friends and patients to injecting- related 
bacterial infections, and a recognition of the need to look 
broader than individual- level interventions.82–84
ETHICS AND DISSEMINATION
As this is a secondary analysis of published literature, no 
ethics approval is required.
By mapping the risk environment for injecting- related 
bacterial and fungal infections among PWID, this study 
aims to identify opportunities for new policy and prac-
tice approaches to prevention. This may include high-
lighting the importance of scaling up access to existing 
interventions (eg, needle/syringe distribution; opioid 
agonist treatment) or identifying opportunities for novel 
combined social and clinical interventions (eg, providing 
Housing First along with antibiotics and addiction treat-
ment for PWID hospitalised with invasive infections). Our 
evidence synthesis may identify opportunities for ‘struc-
tural interventions’, which promote health by altering 
the social–structural context which influence health.46 85 
Examples include the potential impacts of policy or law 
changes (eg, decriminalising substance use may combat 
stigma and facilitate access to primary care of injecting- 
related infections) or of community mobilisation (eg, 
organised PWID empowered to effectively demand safe 
and welcoming hospital care).44 86 87
Incidence of HIV and HCV infections are increasing 
in parallel with injecting- related bacterial and fungal 
infections among PWID, in the context of the North 
American overdose crisis. Although our review focuses 
only on injecting- related bacterial and fungal infections, 
we expect to find that these outcomes share many over-
lapping social–structural correlates.29 45 79 85 88 Secular 
increases in drug- related infections and overdoses over 
Figure 2 Illustrative schematic of a potential risk environment for injecting- related bacterial and fungal infections, as it may 
structure or create infection risk during the process of recognition and adequate treatment of superficial injection- site infections. 
Environmental factors, which are external to individuals, interact to influence individual- level factors and health behaviours 
across stages of a potential pathway: drug acquisition; drug preparation; drug injection; treatment of superficial injection- site 
bacterial and fungal infections (eg, in primary care or emergency departments); treatment of severe/invasive bacterial and fungal 
infections (eg, in hospital for intravenous antibiotics and/or surgery) and health outcomes after severe/invasive bacterial and 
fungal infections (eg, disability, death).
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the past decade have been describes as a ‘syndemic’, with 
shared, fundamental causes rooted in the ‘War on Drugs’ 
and austerity politics.29 42 79 85 Accordingly, findings from 
our study may be able to inform risk reduction interven-
tions for multiple health outcomes among PWID. The 
COVID-19 pandemic has accelerated the overdose death 
crisis, deepened poverty and marginalisation, and inter-
rupted access to harm- reduction services79 85—the conse-
quential impacts on injecting- related bacterial and fungal 
infections, and potential for specific interventions, is not 
yet clear.
The risk environment approach may also help to shift 
beliefs regarding responsibility and risk from individual 
behaviours to social and structural causes, which may 
change attitudes of healthcare professionals and systems 
regarding treatment of severe infections, including 
procedures such as heart valve replacement surgeries for 
injecting- related infective endocarditis.89–91 This may also 
inform educational and behaviour- change interventions, 
highlighting the importance of addressing more imme-
diate, pragmatic priorities (eg, housing and income, or 
vein access and care) that may also have benefits in infec-
tion risk reduction.92 Extending further concepts from 
the HIV prevention social science literature, we are also 
interested in how our findings may relate to interventions 
in social networks.93 Social relationships within networks 
of PWID influence the likelihood of individual risk or 
protective behaviours (eg, needle re- use; skin cleaning). 
Although bacterial and fungal infections are generally 
not transmitted through blood, as is HIV or HCV, PWID 
in the same network may experience transmission of 
colonisation with pathogenic bacteria (eg, MRSA)94 or 
heightened risk of accessing a shared, contaminated drug 
supply (eg, outbreaks of botulism3 95 or anthrax96).
By emphasising the potential importance of social and 
structural factors, the findings will also inform future 
epidemiological research using large- scale linked admin-
istrative, data linking individual and clinical risk factors 
with information on social factors.69 97 Knowledge transla-
tion activities will include peer- reviewed academic publi-
cations and conference presentations, meetings with drug 
user groups/unions and harm reduction programmes, 
and also communications to the lay public in targeted 
outlets.
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